Biodesix Reports Q1 2026 Earnings with Revenue Growth and Improved Margins
Biodesix (BDSX) reported Q1 2026 earnings with total revenue of $25.6 million, a 42% year-over-year increase driven by diagnostic testing and development services. The company also saw improvements in gross margin and a reduction in net loss compared to the prior year.
Topics: development services diagnostic testing earnings financial performance revenue growth